Class
Kinase Inhibitor
MOA
Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT- 3 RET, RET/ PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß) Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and poptosis.
Indications
Side Effects
Dose
400 mg orally twice daily without food (at least 1 hour before or 2 hours after a meal) until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity.
Pack Size: 60’s, 120’s
Storage (°C.): 25°-30° C
Strength: 200 mg Tablets
